Abdulaziz Wannas Abd, Ahmed Kadem Challab
Received 13 March 2017, Accepted 20 May 2017, Available online 30 June 2017
The aim of study is to determine the benefit of In Bios kala-azar detect rapid test in comparative with IFA test in cases with clinical suspicion of visceral leishmaniasis. Eighty four patients with clinical diagnosis of were studied in children and maternity teaching hospital in Al-Diwaniah/Iraq for children and all specimens were checked by using the Kala-azar detect rapid test and rechecked after that by using immunofluorescence antibody test, after that the patients sera were sent for immune-flourescent antibody tests test to confirm or to exclude the diagnosis of the kala-azar. In a current study of eight four (84) patients were clinically suspected as kala-azar (visceral leishmaniasis) using the main two common laboratory investigation (InBios kala-azar detect rapid test and IFA test). The diagnosis of visceral leishmaniasis depend on clinical suspicion of the common signs and symptoms of the disease in areas highly endemic with kala-azar; hepatomegaly in 40/84 patients (7.6%) and splenomegaly founded in 81/84 (96.4%). Fever and pallor were detected in almost all patients through the first clinical attack of visceral leishmaniasis 84/84 (100%). Kala-azar detect rapid test truly positive only in about 72/84 with sensitivity reach (85.71%) the in compares to other test; direct immuno-flourecenc antibody (IFA) test in which the sensitivity of the test reach to (98.8%); and the InBios kala-azar detect rapid test appear positive in only one case from control group thirty (30), diagnosed clinically as a typhoid fever in which the specificity of the test were (96.9 %). In conclusion, the kala-azar detect rapid test is a sensitive, not invasive, rapid, easy to give result within minutes and low cost diagnostic method to be used for the diagnosis of kala-azar but should not use as the sole criterion for the diagnosis of the visceral leishmaniasis unless the signs and symptoms present.
Keywords: Kala-azar; Immunoflourecenc antibody (IFA); Leishmaniasis
Get Full Access/PDF